Welcome to Hodoodo Chemicals

Pomalidomide

CAT#: H202310

CAS#: 19171-19-8

Description: Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.

Synthetic Routes

Pomalidomide - Synthetic Route 1

Synthetic reference

Huang, Daowei; Shen, Chengwu; Wang, Wenya; Huang, Lei; Ni, Feng; Li, Jianqi. New synthesis route for the preparation of pomalidomide. Synthetic Communications. Volume 46. Issue 16. Pages 1343-1348. Journal; Online Computer File. (2016).

Pomalidomide - Synthetic Route 2

Synthetic reference

Wu, Gang; Cen, Jun-da. Improved synthesis of antitumor agent pomalidomide. Zhongguo Yaowu Huaxue Zazhi. Volume 23. Issue 2. Pages 108-110. Journal. (2013).

Pomalidomide - Synthetic Route 3

Synthetic reference

: Tang, Mei; Wu, Han; Zhang, Aiying; Liu, Zenglu; Mao, Zhenmin. Synthesis of antitumor agent pomalidomide. Zhongguo Yiyao Gongye Zazhi. Volume 40. Issue 10. Pages 721-723. Journal. (2009).

Pomalidomide - Synthetic Route 4

Synthetic reference

Crews, Craig M.; Burslem, George; Cromm, Philipp M.; Jaime-Figueroa, Saul; Toure, Momar. Preparation of imide-based compounds as modulators of proteolysis and methods of use. Assignee Yale University, USA. WO 2019148055. (2019).

Pomalidomide - Synthetic Route 5

Synthetic reference

Barman, Dhiren Chandra; Ram, Sita; Rajbangshi, Mantu; Nath, Asok; Prasad, Mohan. Process for the preparation of pomalidomide. Assignee Sun Pharmaceutical Industries Limited, India. WO 2018154516. (2018).

Pomalidomide - Synthetic Route 6

Synthetic reference

: Li, Jianqi; Huang, Daowei; Zhou, Ainan; Liu, Yu; Zhu, Meiyu. A process for preparing pomalidomide for treatment of multiple myeloma via intramolecular cyclization. Assignee Shanghai Institute of Pharmaceutical Industry, Peop. Rep. China; China State Institute of Pharmaceutical Industry. CN 103724323. (2014).

Pomalidomide - Synthetic Route 7

Synthetic reference

: Ni, Cheng; Chen, Hongxiang; Jiang, Weibin; Tang, Jiantuo. Process for preparation of Pomalidomide. Assignee Hangzhou Heze Pharmaceutical Technology Co., Ltd., Peop. Rep. China. CN 105440013. (2016).